Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Harvard Business School
US Department of Justice
Merck
Covington
Moodys

Generated: June 26, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INSULIN ASPART

Try a free trialSee Plans and Pricing

« Back to Dashboard

Clinical Trials for Insulin Aspart

Trial ID Title Status Sponsor Phase Summary
NCT00046150 12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes. Completed Sanofi Phase 3 The purpose of this study is to compare the safety of HMR 1964 and insulin aspart when used in external pumps with respect to catheter occlusions, GHb assessment, insulin doses, blood glucose parameters, hypoglycemic episodes, unexplained hyperglycemia, adverse events, laboratory data, and vital signs.
NCT00065130 Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes Completed Novo Nordisk A/S Phase 3 This trial is conducted in the United States of America (USA). The purpose of this study is to test whether NovoLog (insulin aspart) is a safe and at least as effective alternative to regular human insulin for the control of blood glucose after meals in women who develop diabetes during pregnancy.
NCT00071448 Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population Completed Novo Nordisk A/S Phase 3 This trial is conducted in the United States of America (USA). The aim of this trial is to to determine whether insulin aspart can be used effectively and safely in paediatric patients.
NCT00082407 Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin Completed Eli Lilly and Company Phase 3 This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT00082407 Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin Completed AstraZeneca Phase 3 This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT00095082 Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes Completed Novo Nordisk A/S Phase 3 This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type I diabetes.
NCT00095446 NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes Completed Novo Nordisk A/S Phase 4 This trial is conducted in the United States of America (USA). The aim of this trial is to assess control of blood sugar, safety, and patient acceptance of insulin aspart compared to insulin lispro, both in insulin pumps, in standard clinical practice.
Trial ID Title Status Sponsor Phase Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Insulin Aspart

Condition Name

Condition Name for Insulin Aspart
Intervention Trials
Diabetes 251
Diabetes Mellitus, Type 2 157
Diabetes Mellitus, Type 1 118
Healthy 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Insulin Aspart
Intervention Trials
Diabetes Mellitus 310
Diabetes Mellitus, Type 2 190
Diabetes Mellitus, Type 1 151
Hyperglycemia 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Insulin Aspart

Trials by Country

Trials by Country for Insulin Aspart
Location Trials
United States 922
Germany 79
India 54
China 51
Denmark 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Insulin Aspart
Location Trials
California 56
Texas 53
Florida 46
Georgia 40
New York 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Insulin Aspart

Clinical Trial Phase

Clinical Trial Phase for Insulin Aspart
Clinical Trial Phase Trials
Phase 4 109
Phase 3 94
Phase 2/Phase 3 3
[disabled in preview] 160
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Insulin Aspart
Clinical Trial Phase Trials
Completed 293
Recruiting 32
Unknown status 12
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Insulin Aspart

Sponsor Name

Sponsor Name for Insulin Aspart
Sponsor Trials
Novo Nordisk A/S 271
Sanofi 16
Eli Lilly and Company 8
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Insulin Aspart
Sponsor Trials
Industry 331
Other 133
U.S. Fed 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Healthtrust
AstraZeneca
Deloitte
Mallinckrodt
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.